BRPI0510717B8 - uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr) - Google Patents

uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)

Info

Publication number
BRPI0510717B8
BRPI0510717B8 BRPI0510717A BRPI0510717A BRPI0510717B8 BR PI0510717 B8 BRPI0510717 B8 BR PI0510717B8 BR PI0510717 A BRPI0510717 A BR PI0510717A BR PI0510717 A BRPI0510717 A BR PI0510717A BR PI0510717 B8 BRPI0510717 B8 BR PI0510717B8
Authority
BR
Brazil
Prior art keywords
diindolylmethane
dim
ltr
indol
ylmethyl
Prior art date
Application number
BRPI0510717A
Other languages
English (en)
Inventor
A Zeligs Michael
Original Assignee
Bioresponse Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioresponse Llc filed Critical Bioresponse Llc
Publication of BRPI0510717A publication Critical patent/BRPI0510717A/pt
Publication of BRPI0510717B1 publication Critical patent/BRPI0510717B1/pt
Publication of BRPI0510717B8 publication Critical patent/BRPI0510717B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

uso de 3,3 diindolilmetano (dim) ou um indol relacionado com dim. a presente invenção diz respeito a composições e métodos para tratar ou prevenir leiomiomas pela administração de diindolilmetano e indóis relacionados com diindolilmetano. a presente invenção também diz respeito a composições e métodos para tratar ou prevenir leiomiomas pela administração de diindolilmetano em combinação com um antagonista de egfr. os métodos fornecem tratamentos não invasivos para leiomiomas.
BRPI0510717A 2004-05-06 2005-05-06 uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr) BRPI0510717B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56947804P 2004-05-06 2004-05-06
US60/569,478 2004-05-06
PCT/US2005/015876 WO2005107747A2 (en) 2004-05-06 2005-05-06 Diindolymethane formulations for the treatment of leiomyomas

Publications (3)

Publication Number Publication Date
BRPI0510717A BRPI0510717A (pt) 2007-11-20
BRPI0510717B1 BRPI0510717B1 (pt) 2019-10-01
BRPI0510717B8 true BRPI0510717B8 (pt) 2021-05-25

Family

ID=35320724

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510717A BRPI0510717B8 (pt) 2004-05-06 2005-05-06 uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)

Country Status (4)

Country Link
US (1) US8080577B2 (pt)
BR (1) BRPI0510717B8 (pt)
CA (1) CA2565721C (pt)
WO (1) WO2005107747A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US20060134243A1 (en) * 2004-12-17 2006-06-22 Bionovo, Inc. Method of using extracts of epimedium species
WO2006083458A2 (en) * 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
US7482029B2 (en) * 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
BRPI0717753B1 (pt) 2006-10-27 2022-04-12 Bioresponse, Llc Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
WO2008067102A2 (en) * 2006-10-30 2008-06-05 The Board Of Regents Of The University Of Nebraska Biomarkers of cancer risk and their use in cancer detection and prevention
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
AU2008285325A1 (en) * 2007-08-08 2009-02-12 Bionovo, Inc. Extracts of Ligustrum lucidum and uses thereof
WO2009033103A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of pueraria lobata willd, ohwi of the leguminosae family and uses thereof
AU2008296176A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family and uses thereof
AU2008296136A1 (en) * 2007-09-07 2009-03-12 Bionovo. Inc. Estrogenic extracts of Scuttelaria barbata D. Don of the Labiatae Family and uses thereof
AU2008296072A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of Astragalus membranaceus Fisch.Bge.Var.mongolicus Bge. of the Leguminosae Family and uses thereof
US20090118301A1 (en) * 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
US20090130118A1 (en) * 2007-11-19 2009-05-21 Bionovo, Inc. Scutellaria barbata extract and combinations for the treatment of cancer
CA2706315A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Anti-cancer therapy with an extract of scutellaria barbata
EP2222323A4 (en) * 2007-11-19 2012-07-25 Bionovo Inc PROCESS FOR PREPARING A CLEANED EXTRACT OF SCUTELLARIA BARBATA D. DON
US8512961B2 (en) * 2007-11-19 2013-08-20 Bionovo, Inc. Methods of detecting and treatment of cancers using Scutellaria barbata extract
CA2721191A1 (en) * 2008-04-14 2009-10-22 Bionovo, Inc. Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
AU2009244315A1 (en) * 2008-05-06 2009-11-12 Bionovo, Inc. Estrogenic extracts for use in treating vaginal and vulvar atrophy
US20090311349A1 (en) * 2008-06-05 2009-12-17 Bionovo, Inc., A Delaware Corporation Method of quantification of multiple bioactives from botanical compositions
CA2727018A1 (en) * 2008-06-06 2009-12-10 Bionovo, Inc. Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
JP2012501974A (ja) * 2008-09-03 2012-01-26 バイオノボ・インコーポレーテッド 癌の処置のための方法および組成物
DE202008012041U1 (de) 2008-09-10 2008-11-27 Kisselew, Wsewolod Iwanowitsch Vaginalzäpfchen auf Basis von 3,3'-Dindolylmethan (Methindol)
AU2010246233A1 (en) * 2009-04-28 2011-12-22 Bionovo, Inc. Method of reducing fat accumulation and inducing weight loss
RU2409363C9 (ru) * 2009-09-18 2013-12-10 Всеволод Иванович Киселев Фармацевтические композиции для пероральной доставки дииндолилметана (dim) и способы применения этих композиций
US10799479B2 (en) 2015-04-10 2020-10-13 Bioresponse, L.L.C. Self-emulsifying formulations of DIM-related indoles
US20200179337A1 (en) * 2016-05-16 2020-06-11 Aktsionernoe Obschestvo "Veles Farma" Means for treating sexually transmitted infections
CN106565587B (zh) 2016-11-11 2018-11-09 南京大学 一种aurkb小分子抑制剂及其应用
EP4157271A1 (en) 2020-05-29 2023-04-05 Boulder Bioscience LLC Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
EP4593826A1 (en) 2022-09-30 2025-08-06 Boulder Bioscience LLC Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718921A (en) 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
FR2676927B1 (fr) 1991-05-29 1995-06-23 Ibf Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant.
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
USRE40792E1 (en) 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
US5948808A (en) * 1997-03-07 1999-09-07 The Texas A&M University System Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
CA2284039A1 (en) 1997-03-18 1998-09-24 Ortho-Mcneil Pharmaceutical, Inc. Methods and kits for treating and diagnosing leiomyomas
US6150395A (en) * 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
US5895787A (en) 1997-10-08 1999-04-20 Designed Nutritional Products, Inc. Treatment of fibromyalgia and related disorders
CA2306110A1 (en) * 1997-10-17 1999-04-29 Mochida Pharmaceutical Co., Ltd. Therapeutic agent of uterine leiomyoma, containing dienogest as effective ingredient
US6086915A (en) 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
IL139172A0 (en) 1998-04-29 2001-11-25 Osi Pharm Inc N- (3-ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4- quinazolinamine mesylate anhydrate and monohydrate
ES2188254T3 (es) 1998-11-19 2003-06-16 Warner Lambert Co N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
US6613792B1 (en) 1999-08-02 2003-09-02 Designed Nutritional Products, Inc. Treatment of premenstrual syndrome and menopause
US6689387B1 (en) 1999-09-23 2004-02-10 Bioresponse Llc Phytochemicals for treatment of mastalgia and endometriosis
US6534085B1 (en) 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
US7384971B2 (en) 1999-09-23 2008-06-10 Bioresponse L.L.C. Phytochemicals for the treatment of cervical dysplasia
DE60130544T2 (de) 2000-03-13 2008-06-26 Biocure, Inc. Embolische zusammensetzungen
US6399645B1 (en) * 2000-03-20 2002-06-04 Maria Bell Chemoprevention and treatment of cervical or vaginal neoplasia
EP1267839B1 (en) 2000-03-24 2007-10-03 Biosphere Medical, Inc. Microspheres for active embolization
US6477229B1 (en) 2000-05-12 2002-11-05 Siemens Medical Solutions Usa, Inc. Radiation therapy planning
US7709520B2 (en) * 2000-10-06 2010-05-04 The Texas A&M University System Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
US20020147155A1 (en) 2001-04-06 2002-10-10 Foster Warren G. Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands
US7348352B2 (en) 2001-10-23 2008-03-25 Bioresponse L.L.C. Diindolylmethane for the treatment of HPV infection
US20030220377A1 (en) 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
US6800655B2 (en) * 2002-08-20 2004-10-05 Sri International Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents

Also Published As

Publication number Publication date
BRPI0510717B1 (pt) 2019-10-01
WO2005107747A3 (en) 2007-01-11
CA2565721A1 (en) 2005-11-17
CA2565721C (en) 2015-10-06
US8080577B2 (en) 2011-12-20
WO2005107747A2 (en) 2005-11-17
US20050267193A1 (en) 2005-12-01
BRPI0510717A (pt) 2007-11-20

Similar Documents

Publication Publication Date Title
BRPI0510717A (pt) uso de 3,3' diindolilmetano (dim) ou um indol relacionado com dim
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
CR7056A (es) Derivados de 3-(4-amidopirrol-2-ilmetilden)-2-indolinona como inhibidores de la protein quinasa
MY207663A (en) Substituted indoles and methods of use thereof
MXPA05010174A (es) Derivados de indol e indolina sustituidos.
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
CY1113734T1 (el) Χημικες ενωσεις
DK1558616T3 (da) Meso-substituerede porphyriner
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
ATE340794T1 (de) Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
MA31150B1 (fr) Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade
BRPI0814958B8 (pt) compostos de indol, e, composição
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
NO20084009L (no) Amidderivat eller salt derav
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
EA200701357A1 (ru) Композиции и способы применения модулятора рецептора 5ht
DE60138605D1 (de) Phenyl-substituierte indole als h3 histaminrezeptorantagonisten
EP1838303A4 (en) USE OF DIINDOLYLMETHAN-RELATED INDOLAS FOR THE TREATMENT AND PREVENTION OF DISEASES RELATED TO THE RESPIRATORY SYNCYTIAL VIRUS
DE60312226D1 (de) Tetrazyklische 3-substituierte indole mit serotoninrezeptoraffinität
DE60307856D1 (de) Antitumorverbindung und ihre therapeutischen verwendungen
WO2008021891A3 (en) Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
ATE517152T1 (de) Chirale indole als zwischenprodukte und daraus hergestellte cyaninfluoreszenzfarbstoffe mit funktionellen gruppen
WO2003072558A3 (en) Arylsulfone derivatives
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
UY25825A1 (es) Procedimiento para preparar derivados de indol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: BIORESPONSE, LLC (US)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2773 DE 27-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.